Ligand id: 7988

Name: nimotuzumab

Compound class Antibody
Approved drug? Yes
International Nonproprietary Names
INN number INN
8545 nimotuzumab
h-R3 | THERACIM® | Theraloc®
Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1].

Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar
Database Links
Specialist databases
IMGT/mAb-DB 76
Other databases
GtoPdb PubChem SID 249565669
Search PubMed clinical trials nimotuzumab
Search PubMed titles nimotuzumab
Search PubMed titles/abstracts nimotuzumab
Wikipedia Nimotuzumab